Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.COGT · Entity 3793 | Director | June 09, 2026 | June 11, 2026 |
| Epizyme, Inc.EPZM · Entity 12703 | See Remarks | August 16, 2021 | August 18, 2021 |
| Verastem, Inc.VSTM · Entity 5242 | Chief Operating Officer | April 01, 2025 | April 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.98 · Expires 2036-06-09 | Direct | 17,901 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 17,901 · Balance 17,901 F1: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.
Epizyme, Inc.
Report date August 16, 2021 · Filed August 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 111,313 |
Reported balance
After 2021-08-16 transaction · row 1
1 source rowRow 1 · 2021-08-16 · Grant · Acquired 28,125 · Balance 111,313 F1: Consists of shares of Common Stock issuable under 28,125 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on August 16, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31 · Expires 2031-08-15 | Direct | 134,178 |
Reported balance
After 2021-08-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-16 · Grant · Acquired 134,178 · Balance 134,178 F2: This option was granted on August 16, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 134,178 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of Common Stock issuable under 28,125 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on August 16, 2022.
F2: This option was granted on August 16, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 134,178 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter.
Verastem, Inc.
Report date April 01, 2025 · Filed April 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2025-04-01 transaction · row 1
1 source rowRow 1 · 2025-04-01 · Grant · Acquired 50,000 · Balance 50,000 F1: Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's inducement award program. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the shares subject to the award on the first anniversary of the date of grant and as to an additional 6.25% of the shares at the end of each successive three month period following the first anniversary of the date of grant until the 4th anniversary of the date of grant (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's inducement award program. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the shares subject to the award on the first anniversary of the date of grant and as to an additional 6.25% of the shares at the end of each successive three month period following the first anniversary of the date of grant until the 4th anniversary of the date of grant (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2019 Filed Oct 3, 2019 20:42 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 12,509 | $0.88 Strike: $1.41 | $11,000.41 |
DisclosureSEC source: 0001209191-19-052270 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,509 Underlying: Common Stock · 12,509 shares Expires 2029-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| July 26, 2019 Filed Jul 29, 2019 20:10 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 28,661 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001209191-19-043472 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,661 Underlying: Common Stock · 28,661 shares Expires 2029-07-26 F1 · derivative.exercise_date: This stock option shall vest in 36 equal monthly installments; subject to continued service to the Issuer. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 22:54 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 1,185 | $12.10 | $14,338.50 |
DisclosureSEC source: 0000899243-19-017099 · doc4.xml · nonDerivative · entry 2 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,032 F2 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 22:54 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-017099 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,217 F1 · price: Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Read SEC document |
| January 24, 2019 Filed Jan 29, 2019 01:18 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 151,620 | $0.00 Strike: $9.12 | $0.00 |
DisclosureSEC source: 0000899243-19-002093 · doc4.xml · derivative · entry 2 Ros Matthew · CIK 0001673802 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,620 Underlying: Common Stock · 151,620 shares Expires 2029-01-23 F2 · derivative.exercise_date: This option was granted on January 24, 2019 pursuant to the Company's 2013 Stock Incentive Plan with respect to 151,620 shares of Common Stock, with 25% vesting on January 24, 2020 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 24, 2019 Filed Jan 29, 2019 01:18 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock | 32,894 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-002093 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,217 F1 · shares: Consists of shares of Common Stock issuable under 32,894 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on January 24, 2020 Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 22:08 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 106,344 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009640 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,344 Underlying: Common Stock · 106,344 shares Expires 2028-02-08 F1 · derivative.exercise_date: This option was granted on February 9, 2018 pursuant to the Company's 2013 Stock Incentive Plan with respect to 106,344 shares of Common Stock, with 25% vesting on February 9, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 21:26 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionStock Option (Right to Buy) · Derivative | 72,264 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001209191-18-007843 · doc4.xml · derivative · entry 4 Ros Matthew · CIK 0001673802 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,264 shares Expires 2027-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 21:26 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 519 | $17.20 | $8,926.80 |
DisclosureSEC source: 0001209191-18-007843 · doc4.xml · nonDerivative · entry 3 Ros Matthew · CIK 0001673802 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,603 Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 21:26 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommons Stock, par value $0.0001 | 71,745 | $16.63 | $1,192,767.80 |
DisclosureSEC source: 0001209191-18-007843 · doc4.xml · nonDerivative · entry 2 Ros Matthew · CIK 0001673802 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,122 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 per share to $17.15 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 21:26 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommons Stock, par value $0.0001 | 72,264 | $9.58 | $692,289.12 |
DisclosureSEC source: 0001209191-18-007843 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:03 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon stock, par value $0.0001 | 1,708 | $6.21 | $10,612.66 |
DisclosureSEC source: 0001209191-17-016504 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,708 F1 · shares: These shares were acquired under the Epizyme, Inc. 2013 Employee Stock Purchase Plan in connection with offering period ended February 28, 2017. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:53 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 109,866 | $0.00 Strike: $12.45 | $0.00 |
DisclosureSEC source: 0001209191-17-009196 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,866 Underlying: Common Stock · 109,866 shares Expires 2027-02-07 F1 · derivative.exercise_date: This option was granted on February 8, 2017 pursuant to the Company's 2013 Stock Incentive Plan with respect to 109,866 shares of Common Stock, with 25% vesting on February 8, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.